The strategic use of antiestrogens to control the development and growth of breast cancer.
about
Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 PathwaysChronic tamoxifen use is associated with a decreased risk of intestinal metaplasia in human gastric epitheliumPerspectives in cancer chemoprevention.Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancerIn-vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models.Synthesis and Pharmacological Evolution of Tetrahydroisoquinolines as Anti Breast Cancer Agents.Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapySuppression of tumour development by substances derived from the diet--mechanisms and clinical implications.In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic drugsEstrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.The effect of estrogen on prolidase-dependent regulation of HIF-1α expression in breast cancer cells.Tamoxifen induces rapid, reversible atrophy, and metaplasia in mouse stomach.Synthesis and biological activity of 3-N-substituted estrogen derivatives as breast cancer agents.Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells.Synthesis and Biological Evaluations of Ring Substituted Tetrahydroisoquinolines (THIQs) as Anti-Breast Cancer Agents.
P2860
Q27315022-2D632DD0-89B2-4AD0-A909-EE7059577C1AQ33670993-10BB0190-01F3-4ED7-BA29-DFB2628EDDC1Q34638729-9073AF6A-DE20-4383-980C-405F29E4ED0DQ34684291-BB5F9B65-783F-4043-8398-6B88A1F49A96Q34688033-1BCFDA75-48B1-4136-95B0-0F26AD59AAE3Q34707783-3AFAEE8A-4765-4DD1-9168-2C9ED3766DE5Q35456938-0CFE3CDC-C09B-447D-AA54-DA9DA9C3E763Q35803133-4CF67D71-8006-46C8-B397-17670F8B4FA7Q35992843-E041634C-7C8A-43DA-8085-84EED7E3B1F9Q36456030-3D97BF13-876D-465F-B9D4-5A6328771D31Q36882451-C472E017-47BA-4806-88AB-DBBB45A9F159Q37003243-EDADF538-65B7-4930-AD43-800719C8D318Q37130350-55717394-2C72-4146-96F3-0D56A75ED5E5Q37232505-FC23B47B-235C-4E0C-AEDE-E174F94EFA15Q50073354-90CEFD0A-0A64-4965-A0C2-FA035DB7F647
P2860
The strategic use of antiestrogens to control the development and growth of breast cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
The strategic use of antiestro ...... t and growth of breast cancer.
@ast
The strategic use of antiestro ...... t and growth of breast cancer.
@en
type
label
The strategic use of antiestro ...... t and growth of breast cancer.
@ast
The strategic use of antiestro ...... t and growth of breast cancer.
@en
prefLabel
The strategic use of antiestro ...... t and growth of breast cancer.
@ast
The strategic use of antiestro ...... t and growth of breast cancer.
@en
P1433
P1476
The strategic use of antiestrogens to control the development and growth of breast cancer
@en
P2093
P304
P407
P433
P577
1992-08-01T00:00:00Z